Indian-made 'freeze-free' vaccine carrier to undergo field

Image
Press Trust of India New Delhi
Last Updated : Feb 07 2018 | 8:35 PM IST
An Indian-made "freeze-free" vaccine carrier, which passed the WHO's performance, quality, and safety tests for usage in global immunisation programmes, will begin introductory field trials in Nepal this week, the world health body said today.
This is the first low-cost carrier innovation available to address the widespread and long-standing problem of vaccines freezing in the cold chain during the "last mile" of outreach to infants and children, the WHO said in a statement.
In low and middle income countries, health workers carry millions of temperature-sensitive vaccines next to ice packs inside vaccine carriers to reduce heat exposure, but this risks freezing the vaccines if ice packs are not conditioned (carefully warmed to around 0C).
Freezing can irreversibly compromise vaccine potency, resulting in inadequate protection from disease for people receiving vaccines. When health workers suspect temperature damage, the vaccine or medication is often discarded - at great cost to health care programmes.
PATH's "Freeze-Safe" breakthrough solution mitigates the risk of vaccines being damaged by freezing or heat in carriers and eliminates the step of conditioning ice packs, reducing health worker burden, said Neeraj Jain, country director of PATH's India programme.
Frozen ice packs can be inserted immediately into the carrier thanks to a built-in barrier that shields the vaccines from reaching negative temperatures and excessive heat.
"This 'Made in India' freeze-preventive vaccine carrier can help health workers in India and globally to administer life-saving vaccines that do not freeze and could help save millions of lives," Jain said.
"Our priority is maintaining vaccine potency for the millions of people living in remote communities," said Pat Lennon, who leads the cold chain team at PATH. "In the future, vaccine carriers that prevent freezing will become the new standard for immunisation programmes.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 07 2018 | 8:35 PM IST

Next Story